{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:03Z","timestamp":1707524343932},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,19]]},"DOI":"10.7759\/cureus.16495","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:35:37Z","timestamp":1626741337000},"source":"Crossref","is-referenced-by-count":0,"title":["Ischemic Stroke in a Young Man: Unraveling the Domain of Myeloproliferative Disorders"],"prefix":"10.7759","author":[{"given":"Muhammad Ammar B","family":"Hamid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aasim S","family":"Sehbai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahan","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0198-49","article-title":"An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia","volume":"18","author":"Wiestner A","year":"1998","unstructured":"Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998, 18:49-52. 10.1038\/ng0198-49","journal-title":"Nat Genet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James C","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP, et al.. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434:1144-8. 10.1038\/nature03546","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics R","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, et al.. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005, 352:1779-90. 10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4065\/80.7.947","article-title":"The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis","volume":"80","author":"Tefferi A","year":"2005","unstructured":"Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005, 80:947-58. 10.4065\/80.7.947","journal-title":"Mayo Clin Proc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8588(03)00082-0","article-title":"Essential thrombocythemia","volume":"17","author":"Harrison CN","year":"2003","unstructured":"Harrison CN, Green AR. Essential thrombocythemia. Hematol Oncol Clin North Am. 2003, 17:1175-1190. 10.1016\/s0889-8588(03)00082-0","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/09537100412331272541","article-title":"Abnormal vascular, platelet and coagulation markers in primary thrombocythaemia are not reversed by treatments that reduce the platelet count","volume":"15","author":"Blann A","year":"2004","unstructured":"Blann A, Caine G, Bareford D. Abnormal vascular, platelet and coagulation markers in primary thrombocythaemia are not reversed by treatments that reduce the platelet count. Platelets. 2004, 15:447-9. 10.1080\/09537100412331272541","journal-title":"Platelets"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900801)66:3<549::aid-cncr2820660324>3.0.co;2-6","article-title":"Clinical course of essential thrombocythemia in 147 cases","volume":"66","author":"Fenaux P","year":"1990","unstructured":"Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990, 66:549-556. 10.1002\/1097-0142(19900801)66:3&lt;549::aid-cncr2820660324&gt;3.0.co;2-6","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2000.102005299.x","article-title":"Neurological complications of essential thrombocytosis (ET)","volume":"102","author":"Kesler A","year":"2000","unstructured":"Kesler A, Ellis MH, Manor Y, Gadoth N, Lishner M. Neurological complications of essential thrombocytosis (ET). Acta Neurol Scand. 2000, 102:299-302. 10.1034\/j.1600-0404.2000.102005299.x","journal-title":"Acta Neurol Scand"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo S","year":"1990","unstructured":"Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990, 8:556-62. 10.1200\/JCO.1990.8.3.556","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12928-015-0347-z","article-title":"Acute ST-segment elevation myocardial infarction as the first manifestation of essential thrombocytosis successfully treated with thrombectomy alone","volume":"31","author":"Khaheshi I","year":"2016","unstructured":"Khaheshi I, Memaryan M, Taherkhani M, Serati A, Movahed MR. Acute ST-segment elevation myocardial infarction as the first manifestation of essential thrombocytosis successfully treated with thrombectomy alone. Cardiovasc Interv Ther. 2016, 31:275-8. 10.1007\/s12928-015-0347-z","journal-title":"Cardiovasc Interv Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000480447","article-title":"MTHFR A1298C and C677T polymorphisms are associated with increased risk of venous thromboembolism: a retrospective chart review study","volume":"138","author":"Liu F","year":"2017","unstructured":"Liu F, Silva D, Malone MV, Seetharaman K. MTHFR A1298C and C677T polymorphisms are associated with increased risk of venous thromboembolism: a retrospective chart review study. Acta Haematol. 2017, 138:208-15. 10.1159\/000480447","journal-title":"Acta Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.22546\/36\/843","article-title":"Splenic infarcts-when the cause is multifactorial: MTHF gene mutation and essential thrombocytosis","volume":"77","author":"Pereira M","year":"2016","unstructured":"Pereira M, Morais SA, Pereira N, Lima AL, Barreto V. Splenic infarcts-when the cause is multifactorial: MTHF gene mutation and essential thrombocytosis. Galicia Clin. 2016, 77:75-7. 10.22546\/36\/843","journal-title":"Galicia Clin"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000516471","article-title":"Antithrombotic management in ischemic stroke with essential thrombocythemia: current evidence and dilemmas (IN PRESS)","author":"Das S","year":"2021","unstructured":"Das S, Deb A. Antithrombotic management in ischemic stroke with essential thrombocythemia: current evidence and dilemmas (IN PRESS). Med Princ Pract. 2021, 10.1159\/000516471","journal-title":"Med Princ Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj AP","year":"2006","unstructured":"Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006, 81:159-66. 10.4065\/81.2.159","journal-title":"Mayo Clin Proc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo S","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995, 332:1132-6. 10.1056\/NEJM199504273321704","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison CN","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, et al.. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005, 353:33-45. 10.1056\/NEJMoa043800","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama A","year":"2013","unstructured":"Quint\u00e1s-Cardama A, Abdel-Wahab O, Manshouri T, et al.. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a. Blood. 2013, 122:893-901. 10.1182\/blood-2012-07-442012","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/107602960601200113","article-title":"Extreme thrombocytosis: what are the etiologies?","volume":"12","author":"Wiwanitkit V","year":"2006","unstructured":"Wiwanitkit V. Extreme thrombocytosis: what are the etiologies?. Clin Appl Thromb Hemost. 2006, 12:85-7. 10.1177\/107602960601200113","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/65125-ischemic-stroke-in-a-young-man-unraveling-the-domain-of-myeloproliferative-disorders","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:19Z","timestamp":1707507139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/65125-ischemic-stroke-in-a-young-man-unraveling-the-domain-of-myeloproliferative-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.16495","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,19]]}}}